Skip to main content

Table 2 Additional proportion of variability of the three components that contributed to total pain burden at baseline

From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Additional proportion of variability that contributed to total pain burden at baselinea Episodic migraineb Chronic migrainec
Frequency of monthly migraine headache days 22.6% 13.2%
Duration (hours per migraine headache days) 57.4% 61.1%
Severity of remaining migraine headache days 4.9% 4.8%
  1. aSemi-partial provide the unique (or additional) proportion of variability explained by the particular variable in its ability to predict the outcome after accounting for the other 2 components
  2. bIncludes pooled data from two parallel 6-month studies
  3. cIncludes data from a 3-month study